Non-viral nanovectors for gene delivery: Factors that govern successful therapeutics

Expert Opinion on Drug Delivery

Volumn 7, Issue 6, 2010, Pages 721-735

  Viola, Joana R ^a   El Andaloussi, Samir ^a   Oprea, Iulian I ^a   Smith, Ci Edvard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

In vivo; Intravenous administration; Nanoparticles; Receptor mediated uptake

Indexed keywords

APTAMER; CELL PENETRATING PEPTIDE; LIPOSOME; PLASMID DNA; POLOXAMER; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

CRITICAL MICELLE CONCENTRATION; DNA IMMUNIZATION; GENE EXPRESSION; HALF LIFE TIME; HYDROPHOBICITY; INTERACTIONS WITH DNA; INTERNALIZATION; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PINOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; ZETA POTENTIAL;

GENE TRANSFER TECHNIQUES; GENETIC VECTORS; NANOTECHNOLOGY;

EID: 77952740627     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425241003716810     Document Type: Review

References (134)

1. Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 2008;82(3):171-179
2. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007;25(12):1457-1467
3. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009;10(8):578-585
4. Wooddell CI, Reppen T, Wolff JA, Herweijer H. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery. J Gene Med 2008;10(5):551-563
5. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273(5273):352-354
6. Stenler S, Andersson A, Simonson OE, et al. Gene transfer to mouse heart and skeletal muscles using a minicircle expressing human vascular endothelial growth factor. J Cardiovasc Pharmacol 2009;53(1):18-23
7. Zhang G, Wooddell CI, Hegge JO, et al. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. Hum Gene Ther 2010;21(2):221-237
8. DeLong RK, Akhtar U, Sallee M, et al. Characterization and performance of nucleic acid nanoparticles combined with protamine and gold. Biomaterials 2009;30(32):6451-6459
9. Lin YC, Yu BY, Lin WC, et al. Tailoring the surface potential of gold nanoparticles with self-assembled monolayers with mixed functional groups. J Colloid Interface Sci 2009;340(1):126-130
10. Jin S, Leach JC, Ye K. Nanoparticle-mediated gene delivery. Methods Mol Biol 2009;544:547-557
11. Chang CW, Choi D, Kim WJ, et al. Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. J Control Release 2007;118(2):245-253
12. Viola JR, Leijonmarck H, Simonson OE, et al. Fatty acid-spermine conjugates as DNA carriers for nonviral in vivo gene delivery. Gene Ther 2009;16(12):1429-1440
13. Mae M, Andaloussi SE, Lehto T, Langel U. Chemically modified cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2009;6(11):1195-1205
14. Midoux P, Pichon C, Yaouanc JJ, Jaffres PA. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009;157(2):166-178
15. Walker GF, Fella C, Pelisek J, et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther 2005;11(3):418-425
16. Miller AM, Dean DA. Tissue-specific and transcription factor-mediated nuclear entry of DNA. Adv Drug Deliv Rev 2009;61(7-8):603-613
17. Moreno PM, Wenska M, Lundin KE, et al. A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids. Nucleic Acids Res 2009;37(6):1925-1935
18. Branden LJ, Mohamed AJ, Smith CI. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 1999;17(8):784-787
19. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66(17):2873-2896
20. Akita H, Harashima H. Advances in non-viral gene delivery: using multifunctional envelope-type nano-device. Expert Opin Drug Deliv 2008;5(8):847-859
21. Bloomfield VA. DNA condensation. Curr Opin Struct Biol 1996;6(3):334-341
22. Bloomfield VA. DNA condensation by multivalent cations. Biopolymers 1997;44(3):269-282
23. Geall AJ, Blagbrough IS. Homologation of polyamines in the rapid synthesis of lipospermine conjugates and related lipoplexes. Tetrahedron 2000;56(16):2449-2460
24. Patel MM, Anchordoquy TJ. Contribution of hydrophobicity to thermodynamics of ligand-DNA binding and DNA collapse. Biophys J 2005;88(3):2089-2103
25. Lehto T, Abes R, Oskolkov N, et al. Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. J Control Release 2009;141(1):42-51
26. Mäe M, El Andaloussi S, Lundin P, et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 2009;134(3):221-227
27. Marshall NB, Oda SK, London CA, et al. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods 2007;325(1-2):114-126
28. Kabanov A, Zhu J, Alakhov V. Pluronic block copolymers for gene delivery. Adv Genet 2005;53:231-261
29. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, et al. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci 2006;302(2):522-529
30. Clover B, Hammouda B. SANS from P85/Water-d under pressure. Langmuir 2010 [Epub ahead of print]
31. McIlroy D, Barteau B, Cany J, et al. DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol Ther 2009;17(8):1473-1481
32. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130(2):98-106
33. Roques C, Bouchemal K, Ponchel G, et al. Parameters affecting organization and transfection efficiency of amphiphilic copolymers/DNA carriers. J Control Release 2009;138(1):71-77
34. Braet F, Wisse E, Bomans P, et al. Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions. Microsc Res Tech 2007;70(3):230-242
35. Brissault B, Leborgne C, Guis C, et al. Linear topology confers in vivo gene transfer activity to polyethylenimines. Bioconjug Chem 2006;17(3):759-765
36. Zintchenko A, Susha AS, Concia M, et al. Drug nanocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals. Mol Ther 2009;17(11):1849-1856
37. Harris TJ, Green JJ, Fung PW, et al. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 2009;31(5):998-1006
38. Malek A, Merkel O, Fink L, et al. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 2009;236(1):97-108
39. Hackett PB, Podetz-Petersen KM, Bell JB, et al. Gene expression in lung and liver after intravenous infusion of polyethyleneimine complexes and hydrodynamic delivery of sleeping beauty transposons. Hum Gene Ther 2010;21(2):210-220
40. Barteau B, Chevre R, Letrou-Bonneval E, et al. Physicochemical parameters of non-viral vectors that govern transfection efficiency. Curr Gene Ther 2008;8(5):313-323
41. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation--considerations in the choice of excipients. Expert Opin Drug Deliv 2009;6(11):1219-1230
42. Merdan T, Kunath K, Petersen H, et al. PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice. Bioconjug Chem 2005;16(4):785-792
43. Merkel OM, Beyerle A, Librizzi D, et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm 2009;6(4):1246-1260
44. Trubetskoy VS, Wong SC, Subbotin V, et al. Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther 2003;10(3):261-271
45. Eliyahu H, Joseph A, Schillemans JP, et al. Characterization and in vivo performance of dextran-spermine polyplexes and DOTAP/cholesterol lipoplexes administered locally and systemically. Biomaterials 2007;28(14):2339-2349
46. Zhang W, Tripp RA. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol 2008;82(24):12221-12231
47. Zaghloul EM, Viola JR, Zuber G, et al. Formulation and delivery of splice-correction antisense oligonucleotides by amino acid-modified polyethylenimine. Mol Pharm 2010. [Epub ahead of print]
48. Creusat G, Zuber G. Self-assembling polyethylenimine derivatives mediate efficient siRNA delivery in mammalian cells. Chembiochem 2008;9(17):2787-2789
49. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5(4):505-515
50. Liu L, Zern MA, Lizarzaburu ME, et al. Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Ther 2003;10(2):180-751.
51. Nyunt MT, Dicus CW, Cui YY, et al. Physico-chemical characterization of polylipid nanoparticles for gene delivery to the liver. Bioconjug Chem 2009;20(11):2047-2054
52. Wu J, Lizarzaburu ME, Kurth MJ, et al. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjug Chem 2001;12(2):251-257
53. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-237
54. Beyerle A, Merkel O, Stoeger T, Kissel T. PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure-function relationships. Toxicol Appl Pharmacol 2009;242(2):146-154
55. Kunath K, von Harpe A, Petersen H, et al. The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice. Pharm Res 2002;19(6):810-817
56. Faure AC, Dufort S, Josserand V, et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly (ethylene glycol) coatings. Small 2009;5(22):2565-2575
57. Kojima C, Regino C, Umeda Y, et al. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 2010;383(1-2):293-296
58. Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007;14(1):68-77 (Pubitemid 44942867)
59. Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials 2010;31(2):321-329
60. Kasuya T, Kuroda S. Nanoparticles for human liver-specific drug and gene delivery systems: in vitro and in vivo advances. Expert Opin Drug Deliv 2009;6(1):39-52
61. Oupicky D, Ogris M, Howard KA, et al. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther 2002;5(4):463-472
62. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-178
63. Akinc A, Goldberg M, Qin J, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009;17(5):872-879
64. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008;5(1):25-44
65. Semple SC, Klimuk SK, Harasym TO, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 2001;1510(1-2):152-166
66. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438(7068):685-689
67. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456(7224):980-984
68. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26(5):561-569
69. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105(33):11915-11920
70. Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A. Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 2008;11(2):217-224
71. Lundin P, Johansson H, Guterstam P, et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem 2008;19(12):2535-2542
72. Love K, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. PNAS 2010;107(5):1864-1869
73. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56(11):1649-1659
74. Chisholm EJ, Vassaux G, Martin-Duque P, et al. Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res 2009;69(6):2655-2662
75. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-6392
76. Ogris M, Wagner E. Tumor-targeted gene transfer with DNA polyplexes. Somat Cell Mol Genet 2002;27(1-6):85-95
77. Russ V, Frohlich T, Li Y, et al. Improved in vivo gene transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimine-based polyplexes. J Gene Med 2010;12(2):180-193
78. Pike DB, Ghandehari H. HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev 2010;62(2):167-183
79. Li Z, Huang P, Zhang X, et al. RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. Mol Pharm 2010;7(1):94-104
80. Chen W, Jarzyna PA, van Tilborg GA, et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 2010. [Epub ahead of print]
81. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008;105(45):17356-17361
82. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009;27(9):839-849
83. Huang R, Han L, Li J, et al. Neuroprotection in a 6-hydroxydopamine- lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 2009;11(9):754-763
84. Huang R, Ke W, Han L, et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab 2009;29(12):1914-1923
85. Huang R, Ke W, Liu Y, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 2010;290(1-2):123-130
86. Huang R-Q, Qu Y-H, Ke W-L, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyehtyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007;21:1117-1125
87. Ke W, Shao K, Huang R, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009;30(36):6976-6985
88. Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24(9):1733-1744
89. Rip J, Schenk GJ, de Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv 2009;6(3):227-237
90. Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008;2(6):791-802
91. Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine 2008;3(1):31-49
92. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988;263(29):14621-14624
93. Arangoa MA, Duzgunes N, Tros de Ilarduya C. Increased receptor-mediated gene delivery to the liver by protamineenhanced- asialofetuin-lipoplexes. Gene Ther 2003;10(1):5-14
94. Letrou-Bonneval E, Chevre R, Lambert O, et al. Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes. J Gene Med 2008;10(11):1198-1209
95. Diez S, Navarro G, de ICT. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med 2009;11(1):38-45
96. Sokoloff AV, Wong SC, Ludtke JJ, et al. A new peptide ligand that targets particles and heterologous proteins to hepatocytes in vivo. Mol Ther 2003;8(6):867-872
97. Ludtke JJ, Sokoloff AV, Wong S, et al. Peptide-mediated targeting of hepatocytes via low density lipoprotein receptor-related protein (LRP). Drug Deliv 2009;16(5):268-273
98. Mukthavaram R, Marepally S, Venkata MY, et al. Cationic glycolipids with cyclic and open galactose head groups for the selective targeting of genes to mouse liver. Biomaterials 2009;30(12):2369-2384
99. Yan AC, Levy M. Aptamers and aptamer targeted delivery. RNA Biol 2009;6(3):316-320
100. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110(5):979-986
101. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294(19):2446-2454
102. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114(9):1702-1712
103. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117(22):2865-2874
104. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116(23):2678-2686
105. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006;34(10):e73
106. McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-1015
107. Shaw BR, Moussa L, Sharaf M, et al. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators. Nucleic Acids Symp Ser (Oxf) 2008;52(1):655-656
108. Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008;16(8):1481-1489
109. Lavigne MD, Yates L, Coxhead P, Gorecki DC. Nuclear-targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo. FASEB J 2008;22(6):2097-2107
110. Richard P, Pollard H, Lanctin C, et al. Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation. J Gene Med 2005;7(1):80-86
111. Heemskerk H, de Winter CL, van Ommen GJ, et al. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann NY Acad Sci 2009;1175:71-79
112. Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther 2010;18(1):109-117
113. Richard P, Bossard F, Desigaux L, et al. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther 2005;16(11):1318-1324
114. Bello-Roufai M, Lambert O, Pitard B. Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency. Nucleic Acids Res 2007;35(3):728-739
115. Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004;32(20):e159
116. Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther 2002;13(14):1767-1775
117. Namgung R, Nam S, Kim SK, et al. An acid-labile temperature-responsive sol-gel reversible polymer for enhanced gene delivery to the myocardium and skeletal muscle cells. Biomaterials 2009;30(28):5225-5233
118. Alakhov V, Moskaleva E, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996;7(2):209-216
119. Yang Z, Sahay G, Sriadibhatla S, Kabanov AV. Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem 2008;19(10):1987-1994
120. Jeon E, Kim HD, Kim JS. Pluronic-grafted poly-(L)-lysine as a new synthetic gene carrier. J Biomed Mater Res A 2003;66(4):854-859
121. Ochietti B, Lemieux P, Kabanov AV, et al. Inducing neutrophil recruitment in the liver of ICAM-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1. Gene Ther 2002;9(14):939-945
122. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv 2004;1(4):321-333
123. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev 2010;62(1):28-41
124. Jean M, Smaoui F, Lavertu M, et al. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies. Gene Ther 2009;16(9):1097-1110
125. Pringle IA, Hyde SC, Gill DR. Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects. Expert Opin Biol Ther 2009;9(8):991-1003
126. Davies LA, McLachlan G, Sumner-Jones SG, et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008;16(7):1283-1290
127. Denk W, Strickler JH, Webb WW. Two-photon laser scanning fluorescence microscopy. Science 1990;248(4951):73-76
128. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006;108(13):4009-4017
129. Kormann MHG, Aneja M, Nica G, et al. Pulmonary messenger RNA application prevents fatal respiratory distress in surfactant protein B deficient mice [abstract]. Hum Gene Ther 2009;20(11):1409-1410
130. Weeke-Klimp AH, Bartsch M, Morselt HW, et al. Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin. J Drug Target 2007;15(9):585-594
131. Linnemann AK, Platts AE, Doggett N, et al. Genomewide identification of nuclear matrix attachment regions: an analysis of methods. Biochem Soc Trans 2007;35(Pt 3):612-617
132. Manzini S, Vargiolu A, Stehle IM, et al. Genetically modified pigs produced with a nonviral episomal vector. Proc Natl Acad Sci USA 2006;103(47):17672-17677
133. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26(5):549-551
134. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol 2009;11(5):510-520